Rising Incidences Of Cancer Across Globe Is Affecting The Direction Of The Cancer Tumor Profiling Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The Cancer Tumor Profiling Market Projected To Expand During 2026–2030?

The candida infection testing market has shown substantial growth over recent years. It is anticipated to expand from $16.72 billion in 2025 to $17.8 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. This historical expansion can be linked to a rise in fungal infection cases, the expanding number of immunocompromised individuals, the enhancement of diagnostic services in hospitals, the implementation of culture-based methods for fungal testing, and growing recognition of antifungal resistance.

The market for candida infection testing is poised for significant expansion in the coming years. This market is projected to reach $22.56 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This anticipated growth is driven by several factors, including the rising need for swift fungal diagnostic solutions, the growing integration of molecular and microbiome testing, the broadening availability of point-of-care fungal tests, increasing financial commitments to infectious disease diagnostics, and a heightened emphasis on individualized antifungal treatments. Key trends anticipated during this period encompass the growing acceptance of molecular techniques for candida detection, the increased utilization of rapid NAAT-based testing, the expanding incorporation of microbiome analysis, the proliferation of hospital-centric fungal diagnostics, and an intensified drive towards the early detection of fungal infections.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

What Influential Factors Are Boosting The Cancer Tumor Profiling Market Demand?

The projected expansion of the candida infection testing market is fueled by the rising occurrence of yeast infections. These infections are fungal in nature, stemming from an excessive proliferation of candida, frequently manifesting in regions like the mouth, genitals, and skin, and typically leading to symptoms such as itching, redness, and discomfort. The main triggers for yeast infections include an abundance of the candida fungus, frequently linked to disruptions in the body’s bacterial balance, compromised immune defenses, or shifts in hormonal levels. To precisely identify the presence of candida overgrowth in such cases, candida infection testing is employed, aiding medical professionals in confirming the condition and determining suitable therapeutic approaches. An illustrative example comes from May 2025, where the UK Health Security Agency, a UK-based government public health body, reported a 4% increase in yeast-related bloodstream infections in England in 2024 versus 2023, escalating from 2,170 to 2,247 reports, with the rate climbing from 3.8 to 3.9 per 100,000 population during that timeframe. Consequently, the escalating frequency of yeast infections is set to stimulate the expansion of the candida infection testing market.

How Are Different Segment Groups Identified Within The Cancer Tumor Profiling Market?

The cancer tumor profiling market covered in this report is segmented –

1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

Subsegments:

1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

Which Trends Are Influencing The Expansion Of The Cancer Tumor Profiling Market?

Companies operating in the candida infection testing market are concentrating on developing technologically advanced solutions, such as fully automated PCR rapid tests for candida detection, to improve diagnostic precision and enhance patient outcomes. A fully automated PCR rapid test for detecting candida is a sophisticated diagnostic instrument that employs polymerase chain reaction (PCR) technology to quickly and accurately identify Candida species in clinical samples. For instance, in May 2024, Bosch Healthcare Solutions GmbH, a Germany-based medical technology manufacturer, introduced a PCR test for candida auris detection on the Vivalytic platform, providing fully automated, rapid testing within an hour at the point of care. This advanced test enables prompt screenings and stands in sharp contrast to traditional culture methods, which typically require one to three days in centralized labs, leading to delays in diagnosis and treatment. Developed for clinical environments, the test is especially advantageous for high-risk patients, allowing for timely diagnosis and intervention to combat the serious health risks associated with C. auris infections.

Who Are The Firms Contributing To The Cancer Tumor Profiling Market Ecosystem?

Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

Access The Complete Cancer Tumor Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

What Is The Largest Regional Market In The Cancer Tumor Profiling Market?

North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Tumor Profiling Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2026, By The Business Research Company

Community Oncology Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Cancer Supportive Care Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795